A Study to Assess the Safety, Pharmacokinetics, and Efficacy of Intravenous (IV) ABBV-303, as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181), in Adults With Advanced Solid Tumors
Clinical trial NCT06158958 · TERMINATED
Trial details
- NCT number
- NCT06158958
- Sponsor
- AbbVie
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2024-02-06
- Primary completion
- 2025-10-22
- Enrollment
- 27
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.